Tesamorelin: The Only FDA-Approved GHRH Analog
From Peptidepedia, the trusted peptide wiki.
Medical Advisory Board
Key Takeaways
Tesamorelin is a lab-made peptide that tells the pituitary gland to make more natural growth hormone.
It can lower deep belly fat, and body changes may start to show after several weeks.
It is FDA-approved for HIV-related lipodystrophy, banned by WADA, and is being studied for brain health in older adults.
Tesamorelin (chemical designation: trans-3-hexenoic acid-modified human GHRH(1-44)) is a synthetic peptide consisting of 44 amino acids identical to endogenous human growth hormone-releasing hormone, with the addition of a trans-3-hexenoic acid group that enhances its stability and bioavailability. Developed by Theratechnologies Inc., it obtained FDA approval for reducing excess abdominal fat in HIV-infected patients experiencing lipodystrophy — a condition of abnormal fat distribution frequently caused by antiretroviral therapy.
Primary benefits include:
Significant visceral adipose tissue reduction
Cardiovascular risk marker improvements including triglyceride and cholesterol ratios
Potential cognitive benefits particularly in older populations
Enhanced body composition without supraphysiological hormone elevation associated with exogenous growth hormone therapy
What Is Tesamorelin?
Tesamorelin is a synthetic GHRH analog consisting of 44 amino acids identical to endogenous human growth hormone-releasing hormone, modified with a trans-3-hexenoic acid group that enhances stability and bioavailability. Developed by Theratechnologies Inc., it is the only FDA-approved growth hormone-releasing hormone analog currently on the market. Other GHRH analogs include CJC-1295 and sermorelin, which are commonly used off-label for similar purposes.
How It Works
Pituitary Stimulation and GH Release
The mechanism involves tesamorelin binding to growth hormone-releasing hormone receptors (GHRH-R) located on somatotroph cells in the anterior pituitary gland. This binding triggers signaling cascades stimulating synthesis and secretion of endogenous growth hormone. The process mimics natural physiological mechanisms by which hypothalamic GHRH regulates hormone production, resulting in pulsatile GH release rather than the continuous elevated levels seen with exogenous GH administration.
IGF-1 Elevation and Metabolic Effects
Released growth hormone subsequently stimulates hepatic production of insulin-like growth factor-1 (IGF-1). Clinical evidence demonstrates tesamorelin administration increases IGF-1 levels by approximately 50-100 ng/mL from baseline. This elevation in IGF-1 mediates composition effects including enhanced lipolysis and increased protein synthesis. The metabolic effects on glucose are complex: while IGF-1 can improve insulin sensitivity, GH itself can cause insulin resistance, and the FDA label includes glucose monitoring as a clinical consideration for tesamorelin use.
Visceral Fat Reduction Mechanism
The most documented effect involves visceral adipose tissue reduction. Growth hormone promotes lipolysis by activating hormone-sensitive lipase in adipocytes, facilitating triglyceride breakdown into free fatty acids and glycerol. Visceral fat cells demonstrate particular responsiveness to GH-mediated lipolysis due to higher beta-adrenergic receptor density and greater lipolytic hormone sensitivity. Studies documented reductions in visceral adipose tissue of 10-18% (measured by CT scan) over 26-52 weeks of treatment.
Neuroprotective and Cognitive Effects
Emerging research suggests potential cognitive benefits, particularly in aging populations. A randomized controlled trial in older adults demonstrated improvements in executive function and verbal memory following 20 weeks of tesamorelin administration. These effects presumably result from IGF-1's neuroprotective properties, including enhanced neuronal survival, synaptic plasticity, and reduced neuroinflammation.
Dosage Protocols
FDA-approved dosing for HIV-associated lipodystrophy is 1.4 mg administered subcutaneously once daily. Note: each Egrifta SV vial contains 2 mg of powder, but only 0.35 mL of the 0.5 mL reconstituted solution (1.4 mg) is administered per dose. Non-approved dosing protocols vary based on individual goals and response characteristics.
Standard Protocol: 1–1.4 mg subcutaneously once daily, typically administered in the morning on an empty stomach or before bedtime. Most users begin at 1 mg to assess tolerance before increasing to 1.4 mg if warranted.
Conservative Protocol: 1 mg daily, which represents the lower bound tested in Phase II dose-ranging studies and still produces meaningful reductions in visceral adiposity.
Cycling Considerations: Although FDA-approved use involves continuous daily administration without cycling, some practitioners recommend cycling protocols such as 5 days on/2 days off or 8-12 weeks on followed by 4 weeks off. For more on structuring peptide cycles, see the peptide cycling guide. Cycling rationale includes preventing potential receptor desensitization and allowing the pituitary to maintain sensitivity to GHRH stimulation. However, clinical trial data supporting specific cycling protocols remains limited, and the pivotal trials demonstrating efficacy used continuous daily dosing.
How to Use / Administration
Tesamorelin administration occurs via subcutaneous injection, typically into abdominal areas with rotating injection sites to prevent lipohypertrophy.
Preparation: Wash hands thoroughly. Allow reconstituted solution to reach room temperature if refrigerated. Inspect solution for particulates or discoloration. It should remain clear and colorless.
Injection Technique: Clean injection site with alcohol swab. Pinch skin fold and insert needle at a 45–90 degree angle depending on body composition. Inject slowly and steadily, then withdraw the needle and apply gentle pressure without rubbing.
Timing Optimization: Administration timing influences efficacy. Morning injection on an empty stomach (at least 2 hours after eating and 30-60 minutes before food) takes advantage of naturally lower insulin levels, as insulin can blunt GH release. Alternatively, bedtime administration aligns with natural nocturnal GH surge. Avoid injection within 2-3 hours of consuming carbohydrates or fats, as elevated blood glucose and free fatty acids can inhibit GH secretion.
Results Timeline
Weeks 1-4:
Significant visible changes typically do not occur during initial periods
GH and IGF-1 levels elevate internally
Some individuals report improved sleep quality, increased energy, and enhanced exercise recovery
Weeks 4-8:
Subtle body composition improvements become noticeable, including mild abdominal bloating reduction
Improved skin quality
Laboratory testing typically shows elevated IGF-1 levels
Weeks 8-16:
More pronounced visceral fat reductions become apparent
Clinical trials demonstrated statistically significant visceral adipose tissue reduction by weeks 12-16
Users often report improved muscle definition, particularly in abdominal regions
Weeks 16-26:
Continued progressive improvement in body composition
The pivotal Phase III trials showed approximately 15-18% reduction in visceral adipose tissue (measured by CT scan) at 26 weeks
Lipid profile improvements, including reduced triglycerides, typically become measurable
Beyond 26 Weeks:
Extended treatment continues maintaining or further improving results
The 52-week extension studies demonstrated sustained benefits with continued use
Research Evidence
Tesamorelin efficacy receives support from robust clinical trial data. The pivotal Phase III trials (Studies 1 and 2) enrolled over 800 HIV-positive patients with lipodystrophy and demonstrated statistically significant visceral adipose tissue reductions compared to placebo. Study 1 showed a mean reduction of 15.2% in visceral adipose tissue (measured by CT scan) versus a 5% increase in the placebo group at 26 weeks.
Cardiovascular Risk Markers: Beyond fat reduction, research documented cardiovascular risk marker improvements. A Journal of Clinical Endocrinology & Metabolism study found tesamorelin treatment reduced triglycerides by approximately 50 mg/dL and improved the total cholesterol to HDL ratio.
Cognitive Research: A 2020 randomized controlled trial published in Annals of Neurology examining tesamorelin's effects on cognition in healthy older adults and those with mild cognitive impairment showed significant improvements in executive function and verbal memory, with corresponding changes in cerebrospinal fluid biomarkers suggesting enhanced neuronal health.
NAFLD: Research into tesamorelin's non-alcoholic fatty liver disease (NAFLD) effects showed hepatic fat content reductions, suggesting potential therapeutic applications beyond current indications.
Stacking
Tesamorelin combines with other peptides or compounds to enhance results, though such combinations lack formal clinical study.
Tesamorelin + Ipamorelin
This combination pairs a GHRH analog with a growth hormone-releasing peptide (GHRP). The theoretical synergy involves stimulating GH release through two complementary pathways, GHRH receptor activation and ghrelin receptor agonism, potentially producing greater GH elevation than either compound alone. Ipamorelin is the most commonly paired GHRP due to its selective GH release and minimal effect on cortisol and prolactin.
Tesamorelin + CJC-1295
Some users combine tesamorelin with CJC-1295 (another GHRH analog with extended half-life), though this approach may prove redundant given their similar mechanisms. The potential overlap in receptor targets means the additive benefit is less established than the tesamorelin + ipamorelin combination.
Tesamorelin + Lifestyle Interventions
The most evidence-supported combination involves pairing tesamorelin with structured exercise and dietary optimization. Clinical trials demonstrated that tesamorelin's benefits were additive to lifestyle modifications, making this the most pragmatic and well-supported approach for most users.
Reconstitution, Storage & Preparation
Tesamorelin typically arrives as lyophilized (freeze-dried) powder requiring reconstitution before use.
Reconstitution Process:
Allow vial to reach room temperature
Use bacteriostatic water (preferred for multi-dose vials) or sterile water
Inject diluent slowly against vial wall, allowing it to run down the side rather than directly onto powder
Gently swirl, never shake, until fully dissolved
The resulting solution should remain clear and colorless
Concentration: Standard reconstitution uses 2 mL bacteriostatic water per 2 mg vial, yielding a 1 mg/mL concentration. This allows convenient dosing with standard insulin syringes.
Storage Guidelines:
Unreconstituted powder: Refrigerate at 2-8°C (36-46°F), protect from light
Reconstituted with bacteriostatic water: Refrigerate, use within 14-28 days
Reconstituted with sterile water: Refrigerate, use within shorter window
Never freeze reconstituted solution
Do not use if cloudy or contains particulates
Side Effects
Tesamorelin demonstrates generally good tolerability, with most adverse effects ranging from mild to moderate severity.
Common Side Effects (occurring in >5% of patients):
Injection site reactions including erythema, pruritus, pain, and swelling, affects approximately 8-13% of users, typically diminishing with continued use and proper injection site rotation
Arthralgia (joint pain) and myalgia (muscle pain), occurs in approximately 10-13% of patients, likely related to GH-mediated fluid retention and tissue effects
Peripheral edema and paresthesias (tingling sensations), affects roughly 5-6% of users
Less Common Side Effects:
Carpal tunnel syndrome symptoms
Glucose intolerance
Hypersensitivity reactions
Patients with pre-existing glucose intolerance should monitor blood sugar carefully, as GH can antagonize insulin action. In the pivotal trials, the odds of developing diabetes were approximately 3.3 times higher with tesamorelin than placebo (roughly 5% versus 1% over 26 weeks), reinforcing the importance of glucose monitoring during treatment.
Contraindications:
Tesamorelin remains contraindicated in patients with:
Active malignancy
Disruption of the hypothalamic-pituitary axis due to conditions such as hypophysectomy or pituitary tumor
Pregnancy
Known hypersensitivity to tesamorelin or mannitol
Legal Status / FDA
Tesamorelin (marketed as Egrifta and Egrifta SV) receives FDA approval exclusively for reducing excess abdominal fat in HIV-infected patients with lipodystrophy. It qualifies as a prescription medication in the United States, requiring valid prescriptions from licensed healthcare providers.
Key Regulatory Points:
FDA-approved for HIV-associated lipodystrophy only
Prescription-only medication; not available over the counter
Off-label use for body composition or anti-aging is not FDA-sanctioned, though physicians may legally prescribe off-label based on clinical judgment
Not a controlled substance under the Controlled Substances Act
Gray-market products without valid prescriptions may vary in purity, potency, and sterility. See how to safely source peptides for guidance
Using tesamorelin for indications other than HIV-associated lipodystrophy constitutes off-label use. While physicians may legally prescribe medications off-label based on clinical judgment, patients should understand that such use has not undergone the same regulatory scrutiny as approved indications.
Sports / WADA Status
Tesamorelin remains prohibited in competitive sports. The World Anti-Doping Agency (WADA) classifies all growth hormone-releasing hormones and their analogs under category S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics) of the Prohibited List. This prohibition applies both in-competition and out-of-competition.
Athletes subject to drug testing should recognize that tesamorelin use constitutes a doping violation. Detection methods for GHRH analogs continue advancing, and the elevated IGF-1 levels resulting from tesamorelin use may trigger additional scrutiny under the GH biomarker test.
Organizations with Tesamorelin Bans:
WADA: Prohibited under S2 category (in- and out-of-competition)
USADA: Prohibited
All sports federations adopting the WADA Prohibited List
Conclusion
Tesamorelin represents a scientifically validated approach to stimulating endogenous growth hormone production, with robust clinical evidence supporting visceral adipose tissue reduction efficacy. Its mechanism of preserving natural pulsatile GH release patterns distinguishes it from exogenous growth hormone therapy and may offer advantages in terms of maintaining physiological feedback regulation.
While FDA-approved only for HIV-associated lipodystrophy, ongoing research into cognitive benefits and metabolic effects suggests broader therapeutic potential. The clinical evidence base is substantially stronger than most peptides in this category, with multiple Phase III trials and long-term extension studies establishing both efficacy and tolerability. Users considering tesamorelin should weigh this substantial evidence against off-label use limitations and ensure proper medical supervision given its prescription-only status and contraindication profile.
Frequently Asked Questions
Most users begin noticing subtle improvements in body composition between weeks 8-12, with more significant visceral fat reduction becoming apparent by weeks 16-26. Clinical trials demonstrated statistically significant results at the 26-week mark.
Tesamorelin stimulates natural GH production rather than introducing exogenous hormone, which maintains physiological pulsatile release patterns and feedback mechanisms. While direct comparison studies remain limited, tesamorelin may offer advantages in terms of reduced pituitary suppression risk, though HGH provides more precise dosing control.
Clinical trials have evaluated tesamorelin use for up to 52 weeks with maintained efficacy and acceptable safety profiles. However, long-term data beyond this period remains limited, and discontinuation typically results in gradual return of visceral fat accumulation.
The FDA-approved protocol involves continuous daily administration without cycling. Some practitioners recommend periodic breaks to prevent theoretical receptor desensitization, though clinical evidence supporting specific cycling protocols remains lacking.
Morning administration on an empty stomach or bedtime injection both represent common approaches. The key consideration involves avoiding injection within 2-3 hours of food intake, particularly carbohydrates, as elevated insulin and blood glucose can blunt GH release.
Tesamorelin remains prohibited by WADA and constitutes a doping violation in competitive sports. Standard employment drug screens typically do not test for peptide hormones, but specialized athletic testing can detect GHRH analogs and their GH/IGF-1 biomarker effects.
Tesamorelin remains contraindicated in patients with active malignancy due to theoretical concerns that elevated GH/IGF-1 could promote tumor growth. However, clinical trials have not demonstrated increased cancer incidence with tesamorelin use in appropriate patient populations.
Reconstituted tesamorelin requires refrigeration at 2-8°C (36-46°F) and light protection. When reconstituted with bacteriostatic water, it remains stable for approximately 14-28 days. Never freeze reconstituted solution.
This content is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any health-related decisions.
References
Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine. 2007;357(23):2359-2370.
Falutz J, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat. Journal of Clinical Endocrinology & Metabolism. 2010;95(9):4291-4304.
Stanley TL, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation. JAMA. 2014;312(4):380-389.
Makimura H, et al. Effects of tesamorelin on cardiometabolic risk factors in HIV-infected patients. Journal of Clinical Endocrinology & Metabolism. 2011;96(9):2831-2838.
Fourman LT, et al. Tesamorelin treatment for liver fat and histology in HIV-associated NAFLD. Journal of Clinical Investigation. 2019;129(11):4608-4615.
Baker LD, et al. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults. Archives of Neurology. 2012;69(11):1420-1429.
Sevigny JJ, et al. Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial. Neurology. 2008;71(21):1702-1708.
Dhillon S. Tesamorelin: A Review of its Use in the Management of HIV-Associated Lipodystrophy. Drugs. 2011;71(8):1071-1091.
FDA Prescribing Information for Egrifta SV (tesamorelin).
World Anti-Doping Agency 2024 Prohibited List.
Spooner LM, et al. Tesamorelin: A Growth Hormone-Releasing Factor Analogue for HIV-Associated Lipodystrophy. Annals of Pharmacotherapy. 2012;46(2):240-247.
Stanley TL, et al. Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat. AIDS. 2011;25(10):1281-1288.
See Related Peptides
CJC-1295
CJC-1295 is a synthetic growth hormone-releasing hormone analog that stimulates the pituitary to produce GH and IGF-1. Learn about uses, dosage protocols, side effects, legal status, and research evidence.
Ipamorelin
Ipamorelin: Selective GH secretagogue for enhanced body composition, recovery, and anti-aging. Doses 200-300mcg 1-3x daily. Minimal side effects, safe & well-tolerated.
Sermorelin
Sermorelin is a synthetic GHRH analog (GRF 1-29) that stimulates natural growth hormone release. Learn about dosage protocols, side effects, clinical research, and legal status.
Related Guides
Best Peptides for Muscle Growth
Compare the best peptides for muscle growth, recovery, and body composition. Evidence-based rankings of CJC-1295, Ipamorelin, GHRP-6, Sermorelin, and more.
Peptide Cycling
Learn when and why to cycle peptides. Understand cycling protocols for growth hormone secretagogues, healing peptides, and metabolic peptides to optimize results and avoid tolerance.
How to Safely Source Peptides: Avoiding Scams and Poor Quality
Learn how to safely source research peptides by verifying Certificates of Analysis, recognizing red flags, understanding purity metrics, and ensuring proper storage. A complete guide to avoiding scams and low-quality suppliers.